<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Main Norovirus vaccines in development.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine type</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Preclinical</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase 1</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase 2</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Virus like particle (VLP)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Vaccine Research Center in Tampere, Finland
     <break/> Combined NoV and Rotavirus (RV) vaccine containing NoV VLPs GII.4 and GI.3 and the oligomeric RV VP6 Studies in mice
     <break/> Institute Pasteur of China
     <break/> A vaccine combining NoV GII.4 and Enterovirus 71 VLPs
     <break/> Studies in animal models
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">National Vaccine and Serum Institute, China,
     <break/> Intramuscolar
     <break/> bivalent
     <break/> GI.1 and GII.4
     <break/> Healthy subjects 6 months-59 years
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Takeda
     <break/> Intramuscolar
     <break/> Bivalent
     <break/> GI.1 and GII.4
     <break/> In children &gt; 6 months, adults, people &gt; 60 years, and military recruits
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Recombinant adenovirus</td>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Vaxart
     <break/> Oral
     <break/> Monovalent
     <break/> GI.1 or GII.4 or bivalent combined in healthy adults
    </td>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">P particles</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Several Research Centers
     <break/> Vaccines combining NoV VPI P domain with RV, hepatitis E, influenza and astrovirus in order to obtain extensive protection. Studies in animal models
    </td>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
</table-wrap>
